CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

Authors: C. Michael Gibson MS, MD, Syed Hassan A. Kazmi MD, Serge Korjian MD, Gerald Chi MD, Adam T. Phillips MD, Sahar Memar Montazerin MD, Danielle Duffy MD, Bo Zheng PhD, Mark Heise PhD, Charles Liss MS, Lawrence I. Deckelbaum MD, Samuel D. Wright PhD, Andreas Gille MD, PhD

Source: Journal of Cardiovascular Pharmacology and Therapeutics, Vol 27 (2022)

Subject Terms: Diseases of the circulatory (Cardiovascular) system, RC666-701, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/1940-4034

Access URL: https://doaj.org/article/43aa47289dd347168bc134341711e1bc